Osteopontin: A key link between immunity, inflammation and the central nervous system

Translational Neuroscience

Volumn 3, Issue 3, 2012, Pages 288-293

  Brown, Amanda ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD44; HIV associated neurocognitive disorder; Integrin; Macrophage; Microglia; Neurodegeneration

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3GAMMA; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; OSTEOPONTIN; OSTEOPROTEGERIN;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; NONHUMAN; OLIGODENDROGLIA; OSTEOCLAST; OSTEOLYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN STRUCTURE; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 84871452000     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/s13380-012-0028-7     Document Type: Article

References (67)

1. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H., Cutting edge: Attenuated experimental autoimmune enchephalomyelitis in eta-1/osteopontin-deficient mice, J. Immunol., 2002, 168, 2096-2099 (Pubitemid 34171807)
2. Hur E. M., Youssef S., Haws M. E., Zhang S. Y., Sobel R. A., Steinman L., Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells, Nat. Immunol., 2006, 8, 74-83 (Pubitemid 46242361)
3. Wung J. K., Perry G., Kowalski A., Harris P. L., Bishop G. M., Trivedi M. A., et al., Increased expression of the remodeling- and tumorigenicassociated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain, Curr. Alzheimer Res., 2007, 4, 67-72 (Pubitemid 46293885)
4. Wirths O., Breyhan H., Marcello A., Cotel M. C., Brück W., Bayer T. A., Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease, Neurobiol. Aging, 2010, 31, 747-757
5. Comi C., Carecchio M., Chiocchetti A., Nicola S., Galimberti D., Fenoglio C., et al., Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline, J. Alzheimers Dis., 2010, 19, 1143-1148
6. Maetzler W., Berg D., Schalamberidze N., Melms A., Schott K., Mueller J. C., et al., Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model, Neurobiol. Dis., 2007, 25, 473-482
7. Iczkiewicz J., Jackson M. J., Smith L. A., Rose S., Jenner P., Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease, Brain Res., 2006, 1118, 239-250 (Pubitemid 44740248)
8. Mattson N., Rüetschi U, Pijnenburg Y. A., Blankenstein M. A., Podust V. N., Li S., et al., Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia, Mol. Med. Report, 2008, 1, 757-761
9. Brown A., Islam T., Adams R., Nerle S., Kamara M., Eger C., et al., Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals, J. Neurovirol., 2011, 17, 382-392
10. McArthur J. C., Steiner J., Sacktor N., Nath A., Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap, Ann. Neurol., 2010, 67, 699-714
11. Navia B. A., Jordan B. D., Price R. W., The AIDS dementia complex: I. Clinical features, Ann. Neurol., 1986, 19, 517-524 (Pubitemid 16085185)
12. Heaton R. K., Franklin D. R., Ellis R. J., McCutchan J. A., Letendre S. L., et al., HIV-associated neurocognitive disorder before and during the era of combination antiretroviral therapy: differences in rates, nature and predictors, J. Neurovirol., 2011, 17, 3-16
13. Heaton R. K., Clifford D. B., Franklin D. R. Jr., Woods S. P., Ake C., Vaida F., et al., HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study, Neurology, 2010, 75, 2087-2096
14. Antinori A., Arendt G., Becker J. T., Brew B. J., Byrd D. A., Cherner M., et al., Updated research nosology for HIV-associated neurocognitive disorders, Neurology, 2007, 69, 1789-1799 (Pubitemid 350059308)
15. Kraft-Terry S. D., Stothert A. R., Buch S., Gendelman H. E., HIV-1 neuroimmunity in the era of antiretroviral therapy, Neurobiol. Dis., 2010, 37, 542-548
16. Burdo T. H., Wood M. R., Fox H. S., Osteopontin prevents monocyte recirculation and apoptosis, J. Leukoc. Biol., 2007, 81, 1504-1511 (Pubitemid 46827973)
17. Marcondes M. C., Lanigan C. M., Burdo T. H., Watry D. D., Fox H. S., Increased expression of monocyte CD44v6 correlates with the development of encephalitis in rhesus macaques infected with simian immunodeficiency virus, J. Infect. Dis., 2008, 197, 1567-1576 (Pubitemid 351706487)
18. Burdo T. H., Ellis R. J., Fox H. S., Osteopontin is increased in HIVassociated dementia, J. Infect. Dis., 2008, 198, 715-722
19. Brown A., Gartner S., Kawano T., Benoit N., Cheng-Mayer C., HLA-A2 down-regulation on primary human macrophages infected with an M-tropic EGFP-tagged HIV-1 reporter virus, J. Leukoc. Biol., 2005, 78, 675-685 (Pubitemid 41292090)
20. Brown A., Zhang H., Lopez P., Pardo C. A., Gartner S., In vitro modeling of the HIV-macrophage reservoir, J. Leukoc. Biol., 2006, 80, 1127-1135 (Pubitemid 44646318)
21. Ziegler-Heitbrock H. W. L., Fingerle G., Ströbel M., Schraut W., Stelter F., Schütt C., et al., The novel subset of CD14+ CD16+ blood monocytes exhibits features of tissue macrophages, Eur. J. Immunol., 1993, 23, 2053-2058 (Pubitemid 23265862)
22. Marder K., Albert S. M., McDermott M. P., McArthur J. C., Schifitto G., Selnes O. A., et al., Inter-rater reliability of a clinical staging of HIVassociated cognitive impairment, Neurology, 2003, 60, 1467-1473 (Pubitemid 36554808)
23. Sacktor N., McDermott M. P., Marder K., Schifitto G., Selnes O. A., McArthur J. C., et al., HIV-associated cognitive impairment before and after the advent of combination therapy, J. Neurovirol., 2002, 8, 136- 142 (Pubitemid 34520894)
24. Anborgh P. H., Wilson S. M., Tuck A. B., Winquist E., Schmidt N., Hart R., et al., New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs, Clin. Chem., 2009, 55, 895-903
25. Letendre S., Marquie-Beck J., Capparelli E., Best B., Clifford D., Collier A. C., et al., Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system, Arch. Neurol., 2008, 65, 65-70
26. Lampe M. A., Patarca R., Iregui M. V., Cantor H., Polyclonal B cell ativation by the Eta-1 cytokine and the development of systemic autoimmune disease, J. Immunol., 1991, 147, 2902-2906
27. Saito Y., Kon S., Fujiwara Y., Nakayama Y., Kurotaki D., Fukuda N., et al., Osteopontin small interfering RNA protects mice from fulminant hepatitis, Hum. Gene Ther., 2007, 18, 1205-1214 (Pubitemid 350261964)
28. Rollo E. E., Hempson S. J., Bansal A., Tsao E., Habib J., Rittling S. R., et al., The cytokine osteopontin modulates the severity of rotavirus diarrhea, J. Virol., 2005, 79, 3509-3516 (Pubitemid 40327939)
29. Patarca R., Saavedra R. A., Cantor H., Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene, Crit. Rev. Immunol., 1993, 13, 225-246 (Pubitemid 2030713)
30. Nau G. J., Liaw L., Chupp G. L., Berman J. S., Hogan B. L., Young R. A., Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin, Infect. Immun., 1999, 67, 4223-4230 (Pubitemid 29357049)
31. Weber G. F., Ashkar S., Glimcher M. J., Cantor H., Receptor-ligand interaction between CD44 and osteopontin/Eta-1, Science, 1996, 271, 509-512
32. Patarca R., Freeman G. J., Singh R. P., Wei F. Y., Durfee T., Blattner F., et al., Structural and functional studies of the early T-lymphocyte activation 1 (Eta-1) gene, J. Exp. Med., 1989, 170, 145-161
33. Ashkar S., Weber G. F., Panoutsakopoulou V., Sanchirico M. E., Jannson M., Zawaideh S., et al., Eta-1 (Osteopontin): An early component of type-1 (cell-mediated) immunity, Science, 2000, 287, 860-864 (Pubitemid 30084330)
34. Wang K. X., Denhardt D. T., Osteopontin: Role in immune regulation and stress responses, Cytokine Growth Factor Rev., 2008, 19, 333-345
35. Shinohara M. L., Lu L., Bu J., Werneck M. B., Kobayashi K. S., Glimcher L. H., et al., Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells, Nat. Immunol., 2006, 7, 498-506
36. Morimoto J., Sato K., Nakayama Y., Kimura C., Kajino K., Matsui Y., et al., Osteopontin modulates the generation of memory CD8+ T cells during influenza virus infection, J. Immunol., 2011, 187, 5671-5683
37. Chabas D., Baranzini S. E., Mitchell D., Bernard C. C., Rittling S. R., Denhardt D. T., et al., The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease, Science, 2001, 294, 1731-1735 (Pubitemid 33104847)
38. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nat. Med., 2002, 8, 500-508 (Pubitemid 34546753)
39. Vogt M. H., Floris S., Killestein J., Knol D. L., Smits M., Barkhof F., et al., Osteopontin levels and increased disease activity in relapsing remitting multiple sclerosis patients, J. Neuroimmunol., 2004, 155, 155-160 (Pubitemid 39165788)
40. Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., Blas Navarro J., et al., Plasma osteopontin levels in multiple sclerosis, J. Neuroimmunol., 2005, 158, 231-239 (Pubitemid 39626091)
41. Braitch M., Nunan R., Niepel G., Edwards L. J., Constantinescu C. S., Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis, Arch. Neurol., 2008, 65, 633-635 (Pubitemid 351679658)
42. Tiberti N., Hainard A., Lejon V., Robin X., Ngoyi D. M., Turck N., et al., Discovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasis, Mol. Cell. Proteomics, 2010, 9, 2783-2795
43. Sodek J., Ganss B., McKeee M. D., Osteopontin, Crit. Rev. Oral Biol. Med., 2000, 11, 279-303
44. Denhardt, D. T., Guo X, Osteopontin: A protein with diverse functions, FASEB J., 1993, 7, 1475-1482 (Pubitemid 24003267)
45. Bellahcène A., Castronovo V., Ogbureke K. U., Fisher L. W., Fedarko N. S., Small integrin-binding ligand N-liked glycoproteins (SIBLINGs): multifunctional proteins in cancer, Nat. Rev. Cancer, 2008, 8, 212-226 (Pubitemid 351301854)
46. Kazanecki C. C., Uzwiak D. J., Denhardt D. T., Control of osteopontin signaling and function by post-translational phosphorylation and protein folding, J. Cell. Biochem., 2007, 102, 912-924 (Pubitemid 350036931)
47. Ransohoff R. M., Cardona A. E., The myeloid cells of the central nervous system parenchyma, Nature, 2010, 468, 253-262
48. Suzuki K., Takeyama S., Sakai Y., Yamada S., Shinoda H., Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts, J. Pharmacol. Sci., 2006, 100, 189-194
49. Ofotokun I., Weitzmann M. N., HIV and bone metabolism, Discovery Med., 2011, 11, 385-393
50. Ofotokun I., Weitzmann M. N., HIV: inflammation and bone, Curr. HIV/ AIDS Rep., 2012, 9, 16-25
51. Clowes J., Riggs B. L., Khosia S., The role of immune system in the pathophysiology of osteoporosis, Immunol. Rev., 2005, 208, 207-227 (Pubitemid 41746395)
52. Pirraco R. P., Reis R. L., Marques A. P., Effect of monocytes/macrophages on the early osteogenic differentiation of hBMSCs, J. Tissue Eng. Regen. Med., 2012, doi: 10.1002/term.535 [Epub ahead of print]
53. Brown T. T., Ross A. C., Storer N., Labbato D., McComsey G. A., Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens, Antivir. Ther., 2011, 16, 1063-1072
54. Vikulina T., Fan X., Yamaguchi M., Roser-Page S., Zayzafoon M., Guidot D. M., et al., Alterations in the immuno-skeletal interface drive bone distruction in HIV-1 transgenic rats, Proc. Natl. Acad. Sci. USA, 2010, 107, 13848-13853
55. Haskelberg H., Carr A., Emery S., Bone turnover markers in HIV disease, AIDS Rev., 2011, 13, 240-250
56. Walker Harris B., Brown T. T., Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies, J. Infect. Dis., 2012, 205 (Suppl. 3), S391-398
57. Coiras M., López-Huertas M. R., Sánchez del Cojo M., Mateos E., Alcamí J., Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle, AIDS Rev., 2010, 12, 103-112
58. Shin S. L., Cha J. H., Chun M. H., Chung J. W., Lee M. Y., Expression of osteopontin mRNA in the adult rat brain, Neurosci. Lett., 1999, 273, 73-76
59. Ichikawa H., Itota T., Nishitani Y., Torii Y., Inoue K., Sugimoto T., Osteopontin-immunoreactive primary sensory neurons in the rat spinal and trigeminal nervous systems, Brain Res., 2000, 863, 276-281 (Pubitemid 30201610)
60. Glezer I., Bittencourt J. C., Rivest S., Neuronal expression of Cd36, Cd44, and Cd83 antigen transcripts maps to distinct and specific murine brain circuits, J. Comp. Neurol., 2009, 517, 906-924
61. Mark M. P., Prince C. W., Gay S., Austin R. L., Butler W. T., 44-kDal bone phosphoprotein (osteopontin) antigenicity at ectopic sites in newborn rats: kidney and nervous tissues, Cell Tissue Res., 1988, 251, 23-30
62. van Velthoven C. T., Heijnen C. J., van Bel F., Kavelaars A., Osteopontin enhances endogenous repair after neonatal hypoxic-ischemic brain injury, Stroke, 2011, 42, 2294-2301
63. Morinobu M., Ishijima M., Rittling S. R., Tsuji K., Yamamoto H., Nifuji A., et al., Osteopontin expression in osteoblasts and osteocytes during bone formation under mechanical stress in the calvarial suture in vivo, J. Bone Miner. Res., 2003, 18, 1706-1715 (Pubitemid 37022930)
64. McKee M. D., Addison W. N., Kaartinen M. T., Hierarchies of extracellular matrix and mineral organization in bone of the craniofacial complex and skeleton, Cells Tissues Organs, 2005, 181, 176-188
65. Iseki S., Wilkie A. O., Heath J. K., Ishimaru T., Eto K., Morriss-Kay G. M., Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2, Development, 1997, 124, 3375-3384 (Pubitemid 27440452)
66. Hazenberg M. D., Stuart J. W., Otto S. A., Borleffs J. C., Boucher C. A., de Boer R. J., et al., T-cell division in human immunodeficiency virus (HIV-1) infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART), Blood, 2000, 95, 249-255 (Pubitemid 30017249)
67. Connoly N., Riffler S., Rinaldo C., Proinflammatory cytokines in HIV disease - a review and rationale for new therapeutic approaches, AIDS Rev., 2005, 7, 168-180 (Pubitemid 41671917)